Nature Search

Capsid-like particles decorated with the SARS-CoV-2 receptor-binding domain elicit strong virus neutralization activity

Here the authors generate a capsid-like particle based vaccine candidate displaying the receptor-binding domain of the SARS-CoV-2 spike protein and show induction of neutralizing antibodies after intramuscular prime-boost immunization in mice.

Cyrielle Fougeroux
Louise Goksøyr
Adam F. Sander
ResearchOpen Access12 Jan 2021
Nature Communications

Volume: 12, P: 1-11
Engineering potent live attenuated coronavirus vaccines by targeted inactivation of the immune evasive viral deubiquitinase

In this work, authors provide a proof-of-concept study showing that deubiquitinating enzyme inactivation in MERS-CoV leads to attenuation in mice, and protection against a lethal challenge.

Sebenzile K. Myeni
Peter J. Bredenbeek
Marjolein Kikkert
ResearchOpen Access28 Feb 2023
Nature Communications

Volume: 14, P: 1-15
Prolonged activation of nasal immune cell populations and development of tissue-resident SARS-CoV-2-specific CD8⁺ T cell responses following COVID-19

The immunological processes occurring in the upper respiratory tract during COVID-19 are relatively poorly understood. Jochems and colleagues observe durable changes in the upper respiratory tract following SARS-CoV-2 infection, including evidence of virus-specific tissue memory T cells.

Anna H. E. Roukens
Cilia R. Pothast
Frits Rosendaal
Research22 Dec 2021
Nature Immunology

Volume: 23, P: 23-32
Ad26 vector-based COVID-19 vaccine encoding a prefusion-stabilized SARS-CoV-2 Spike immunogen induces potent humoral and cellular immune responses

Rinke Bos
Lucy Rutten
Hanneke Schuitemaker
ResearchOpen Access28 Sept 2020
npj Vaccines

Volume: 5, P: 1-11
Ad26.COV2.S protects Syrian hamsters against G614 spike variant SARS-CoV-2 and does not enhance respiratory disease

Joan E. M. van der Lubbe
Sietske K. Rosendahl Huber
Frank Wegmann
ResearchOpen Access19 Mar 2021
npj Vaccines

Volume: 6, P: 1-12

Quick links

Search

Filter By:

Capsid-like particles decorated with the SARS-CoV-2 receptor-binding domain elicit strong virus neutralization activity

Engineering potent live attenuated coronavirus vaccines by targeted inactivation of the immune evasive viral deubiquitinase

Prolonged activation of nasal immune cell populations and development of tissue-resident SARS-CoV-2-specific CD8+ T cell responses following COVID-19

Ad26 vector-based COVID-19 vaccine encoding a prefusion-stabilized SARS-CoV-2 Spike immunogen induces potent humoral and cellular immune responses

Ad26.COV2.S protects Syrian hamsters against G614 spike variant SARS-CoV-2 and does not enhance respiratory disease

Search

Quick links

Prolonged activation of nasal immune cell populations and development of tissue-resident SARS-CoV-2-specific CD8⁺ T cell responses following COVID-19